Work With Us
Every stakeholder. One aligned ecosystem.
Alva10 works with employers, payers, diagnostic developers, and investors — each with a distinct role in bringing better diagnostics to patients. Find your path below.
Select Your Group
How can we help you?
Alva10 understands that each of our partnering groups has a different relationship with the diagnostics ecosystem. Select your affiliation to find the most relevant path forward.
EMPLOYERS
You're managing growing healthcare benefits spend with limited visibility into what's driving costs. Alva10 uses data analytics to identify drivers of healthcare spending gaps in your workforce population, then deploys targeted solutions to reduce total cost of care and improve workforce productivity.
Explore employer solutions →
PAYERS
You need novel diagnostic tools that solve your population's greatest clinical and economic challenges — but the path from diagnostic innovation to payer-ready evidence has historically been unclear. Alva10 bridges that gap.
Explore payer solutions →
DIAGNOSTIC DEVELOPERS & LABS
You're innovating diagnostic technology but facing the industry's perennial challenge: getting to reimbursement without clarity on what payers actually need. Alva10 works with you pre-commercially to define coverage standards, build the right evidence, gain early market traction and contractually commit payers to coverage.
Explore employer solutions →
INVESTORS
You're exploring opportunities in precision diagnostics but need clarity on the capital requirements, evidence thresholds, and market success benchmarks that define a viable investment.
Explore investor resources →
Our Approach
Starting with data analytics — not technology
Most diagnostic companies start by building the technology and then ask payers to pay for it. Alva10 reverses that. We start by using data analytics to understand what the market needs, what clinical problems need to be solved, how clinical workflows fit, what economic value a diagnostic must deliver, and what evidence is required — and then work backwards to source or develop the right tool. This approach ensures that every diagnostic solution we bring to market is built on a foundation of defined clinical utility, economic value, and reimbursement standards from day one.
STEP 01
Identify the Clinical & Economic Gap
We work with employers and payers to analyze population and claims data — surfacing where missed unassessed risk, screening gaps, primary diagnoses, and specialty drug spend are driving the highest costs and poor patient outcomes.
STEP 01
Identify the Clinical & Economic Gap
We work with employers and payers to analyze population and claims data — surfacing where missed unassessed risk, screening gaps, primary diagnoses, and specialty drug spend are driving the highest costs and poor patient outcomes.
STEP 02
Define Clinical Utility Upfront
We align with clinicians, employers, and payers to define the clinical problem to be solved, and how to solve it, enabling alignment on requirements for clinical utility, value proposition, and evidence thresholds required for early market deployment through pilot studies and contractually defined coverage.
STEP 03
Source or Develop the Right Tool
We curate best-in-class diagnostic technologies from our precision medicine portfolio, or partner with diagnostic developers to build and validate the specific tool required.
STEP 04
Drive Payment, Access & Patient Impact
With evidence standards agreed and met, employers and payers pay for the diagnostic, physicians use it, and patients benefit. Investors see a clear path to return on investment.
For Diagnostic Developers
Where diagnostic development goes wrong
There is a persistent tendency in the diagnostics industry to focus the majority of early resources on technical challenges — while the market-facing questions that determine commercial success go unanswered until it's too late.
OVER-RESOURCED
TECHNICAL CHALLENGES
Biomarker discovery
Assay development
Analytical validity
Clinical validity
Sample type & stability
Regulatory & coding
Software integration
UNDER-RESOURCED
Who pays for the technology?
How much evidence is required for coverage?
Are the clinical utility assumptions correct?
What is the agreed value proposition?
Who is incentivized to block market entry?
Barriers to payment & access?
Path to KOL & community adoption?
MARKET-LIMITING CHALLENGES
The Diagnostic Development Cycle
Vicious cycle vs. virtuous cycle
The standard diagnostic development model — build first, seek payment last — has created a 'valley of death' for the industry. Alva10 flips the model, bringing market alignment to the start of the process.
THE VICIOUS CYCLE
(THE PROBLEM)
THE VIRTUOUS CYCLE
(THE ALVA10 SOLUTION)
1. Develop test based on KOL input — without payer input
2. Launch to market and ask payers for pilot studies
3. Payer sees incomplete product with insufficient evidence
4. Payer deems test experimental, declines coverage
5. Developer returns to investors with no clear path to success Outcome: 'This is the valley of death for diagnostics — technically excellent products that never reach patients.'
1. Engage with the market pre-commercially — define clinical utility and evidence standards
2. Define evidence plan, reimbursement, and coverage standards
3. Raise capital with confidence — investors see a defined path to reimbursement
5. Employers use and payers covers the diagnostic — patients benefit, investors see their return Outcome: 'A win-win-win: you reach the market, the market gets what it needs, investors see their return.'
4. Generate evidence precisely to agreed standards — no wasted spend
A win for every stakeholder
DIAGNOSTIC COMPANIES
A funded, clear path to market with clearly defined evidence standards, alignment on clinical utility, early market access with incentivized parties.
PAYERS & EMPLOYERS
Payment grounded in aligned clinical utility and economic impact — eliminating both wasted healthcare spend and wasted resources reviewing insufficient evidence on point solution.
INVESTORS
A contractually-defined path to ROI with clear capital requirements, evidence milestones, and market success benchmarks.
